Monitoring the response of patients with locally advanced breast carcinoma to neoadjuvant chemotherapy using [technetium 99m]-sestamibi scintimammography

Cancer

Volumn 85, Issue 11, 1999, Pages 2410-2423

  Mankoff, David A ^a,d   Dunnwald, Lisa K ^a   Gralow, Julie R ^a   Ellis, Georgiana K ^a   Drucker, Mariann J ^b,c   Livingston, Robert B ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c Fred Hutchinson Cancer Research Center   (United States)

^d Division of Nuclear Medicine   (United States)

Author keywords

Breast carcinoma; Neoadjuvant chemotherapy; Scintimammography; Sestamibi

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUOROURACIL; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; TAMOXIFEN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BREAST CARCINOMA; CANCER ADJUVANT THERAPY; CLINICAL ARTICLE; DIAGNOSTIC ACCURACY; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LYMPH NODE METASTASIS; MALE; MINIMAL RESIDUAL DISEASE; MONITORING; PRIORITY JOURNAL; SCINTIMAMMOGRAPHY;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; FEASIBILITY STUDIES; FEMALE; HUMANS; LYMPHATIC METASTASIS; MAMMOGRAPHY; MIDDLE AGED; MONITORING, PHYSIOLOGIC; NEOADJUVANT THERAPY; REPRODUCIBILITY OF RESULTS; TECHNETIUM TC 99M SESTAMIBI; TREATMENT OUTCOME;

EID: 0033151794     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19990601)85:11<2410::AID-CNCR16>3.0.CO;2-K     Document Type: Article

References (44)

1. Beahrs O. Staging of cancer. CA Cancer J Clin 1991;41:121-5.
2. Hortobagyi GN, Ames FC, Buzdar AU, Kau SW, McNeese MD, Paulus D, et al. Management of stage III primary breast cancer with primary chemotherapy, surgery, and radiation therapy. Cancer 1988;62:2507-16.
3. Miller BA, Feuer EJ, Hankey BF. Recent incidence trends for breast cancer in women and the relevance of early detection: an update. CA Cancer J Clin 1993;43:27-41.
4. Schwartz GF, Birchansky CA, Komarnicky LT, Mansfield CM, Cantor RI, Biermann WA, et al. Induction chemotherapy followed by breast conservation for locally advanced carcinoma of the breast. Cancer 1994;73:362-9.
5. Booser DJ, Hortobagyi GN. Treatment of locally advanced breast cancer. Semin Oncol 1992;19:278-85.
6. Hortobagyi GN. Comprehensive management of locally advanced breast cancer. Cancer 1990;66:1387-91.
7. Smith IE, Walsh G, Jones A, Prendiville J, Johnston S, Gusterson B, et al. High complete remission rates with primary neoadjuvant infusional chemotherapy for large early breast cancer. J Clin Oncol 1995;13:424-9.
8. Reubens RD, Bartelink H, Engelsman E, Hayward JL, Rotmensz N, Sylvester R, et al. Locally advanced breast cancer: the contribution of cytotoxic and endocrine treatment to radiotherapy. An EORTC breast cancer co-operative trial (10792). Eur J Cancer 1989;4:667-78.
9. Swain SM, Sorace RA, Bagley CS, Danforth DN Jr., Bader J, Wesley MN, et al. Neoadjuvant chemotherapy in the combined modality approach of locally advanced nonmetastatic breast cancer. Cancer Res 1987;47:3889-94.
10. Bonadonna G, Valagussa P, Zucali R, Salvadori B. Primary chemotherapy in surgically resectable breast cancer. CA Cancer J Clin 1995;45:227-43.
11. Feldman LD, Hortobagyi GN, Buzdar AU, Ames FC, Blumenschein GR. Pathological assessment of response to induction chemotherapy in breast cancer. Cancer Res 1986;46: 2578-81.
12. Cocconi G, DiBlasio B, Alberti G, Bisagni G, Botti E, Peracchia G. Problems in evaluating the response of primary breast cancer to systemic therapy. Breast Cancer Res Treat 1984;4:309-13.
13. Segel MC, Paulus DD, Hortobagyi GN. Advanced primary breast cancer: assessment at mammography of response to chemotherapy. Radiology 1988;169:49-54.
14. Moscovic EC, Mansi JL, King DM, Murch CR, Smith E. Mammography in the assessment of response to medical treatment of large primary breast tumor. Clin Radiol 1993;47: 339-44.
15. Kedar RP, Cosgrove DO, Smith IE, Mansi JL, Bamber JC. Breast carcinoma: measurement of tumor response to primary medical therapy with color flow Doppler imaging. Radiology 1994;190:825-30.
16. 18F]fluorodeoxyglucose scintigraphy in diagnosis and follow up of treatment in advanced breast cancer. Eur J Nucl Med 1989;15:61-6.
17. Wahl R, Zasadny K, Helvie M, Hutchins G, Weber B, Cody R. Metabolic monitoring of breast cancer chemohormonotherapy using positron emission tomography: initial evaluation. J Clin Oncol 1993;11:2101-11.
18. Bassa P, Kim EE, Inoue T, Wong FC, Korkmaz M, Yang DJ, et al. Evaluation of preoperative chemotherapy using PET with fluorine-18-fluorodeoxyglucose in breast cancer. J Nucl Med 1996;37:931-8.
19. Abraham DC, Jones RC, Jones SE, Cheek JH, Peters GN, Knox SM, et al. Evaluation of neoadjuvant chemotherapeutic response of locally advanced breast cancer by magnetic resonance imaging. Cancer 1996;78:91-100.
20. Gilles R, Guinebretiere JM, Toussaint C, Spielman M, Rietjans M, Petit JY, et al. Locally advanced breast cancer: contrast-enhanced subtraction MR imaging of response to preoperative chemotherapy. Radiology 1994;191:633-8.
21. Khalkahli I, Mena I, Jouanne E, Diggles L, Venegas R, Black J, et al. Prone scintimammography in patients with suspicion of carcinoma of the breast. J Am Coll Surg 1994;178:491-7.
22. Scopinaro F, Schillaci O, Scarpini M, Mingazzini PL, DiMacio L, Banci M, et al. Technetium-99m sestamibi: an indicator of breast cancer invasiveness. Eur J Nucl Med 1994;21: 984-7.
23. Taillefer R, Robidoux A, Lambert R, Turpin S, Laperriere J. Technetium-99m-sestamibi prone scintimammography to detect primary breast cancer and axillary lymph node involvement. J Nucl Med 1995;36:1758-65.
24. Carvalho PA, Chiu ML, Kronauge JF, Kawamura M, Jones AG, Holman BL, et al. Subcellular distribution and analysis of technetium-99m-MIBI in isolated perfused rat hearts. J Nucl Med 1992;33:1516-21.
25. Crane P, Laliberte R, Heminway S, Thoolen M, Orlndi C. Effect of mitochondrial viability and metabolism on technetium-99m-sestamibi myocardial retention. Eur J Nucl Med 1993;20:20-5.
26. Piwnica-Worms D, Kronauge JF, Chiu ML. Uptake and retention of hexakis (2-methoxyisobutyl isonitrile) technetium (I) in cultured chick myocardial cells. Mitochondrial and plasma membrane potential dependence. Circulation 1990; 82:1826-38.
27. Okada RD, Glover D, Gaffney T, Williams S. Myocardial kinetics of technetium-99m hexakis 2-methoxy-2methylpropyl-isonitrile. Circulation 1988;77:491-8.
28. Wilson CBJH, Lammertsma AA, McKenzie CG, Sikora K, Jones T. Measurements of blood flow and exchanging water space in breast tumors using positron emission tomography: a rapid and non-invasive dynamic method. Cancer Res 1992;52:1592-7.
29. Delmon-Moingeon LI, Piwnica-Worms D, Abbeele ADVD, Holman BL, Davison A, Jones AG. Uptake of the cation hexakis(2-methoxyisobutylisonitrile)-technetium-99m by human carcinoma cell lines in vitro. Cancer Res 1990;50: 2198-202.
30. Maini CL, Tofani A, Sciuto R, Semprebene A, Cavaliere R, Mottolese M, et al. Technetium-99m-MIBI scintigraphy in the assessment of neoadjuvant chemotherapy in breast carcinoma. J Nucl Med 1997;38:1546-50.
31. Nagaraj N, Ashok G, Waxman A, Kovalevsky M, Youssim C, Forscher C, et al. Clinical usefulness of serial Tc-99m sestamibi (MIBI) scintigraphy in evaluating tumor response to preop chemotherapy in patients with bone and soft tissue sarcomas. J Nucl Med 1995;36:129P.
32. Pinder SE, Wencyk P, Sibbering DM, Bell JA, Elston CW, Nicholson R, et al. Assessment of the new proliferation marker MIBI in breast carcinoma using image analysis: associations with other prognostic factors and survival. Br J Cancer 1995;71:146-9.
33. Diggles L, Mena I, Khalkhali I. Technical aspects of prone dependent-breast scintimammography. J Nucl Med Technol 1994;22:165-70.
34. Dunnwald LK, Hartnett SD, Mankoff DA. Utility and reproducibility of semiquantitative analysis of sestamibi breast images. J Nucl Med Technol 1997;25:106-9.
35. Hayward JL, Carbone PP, Heuson J-C, Kumaoka S, Segaloff A, Reubens RD. Assessment of response to therapy in advanced breast cancer. Cancer 1977;39:1289-94.
36. Machiavelli M, Romero A, Pérez J, Lacava J, Domínguez M, Rodríguez R, et al. Prognostic significance of pathological response of primary tumor and metastatic axillary lymph nodes after neoadjuvant chemotherapy for locally advanced breast carcinoma. Cancer J Sci Am 1998;4:125-31.
37. Hanley J, McNeil B. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 1982;143:29-36.
38. Piwnica-Worms D, Kronauge JF, Delmon L, Holman BL, Marsh JD, Jones AG. Effect of metabolic inhibition on technetium-99m-MIBI kinetic in cultured chick myocardial cells. J Nucl Med 1990;31:464-72.
39. Piwnica-Worms D, Chiu ML, Budding M, Kronauge JF, Kramer RA, Croop JM. Functional imaging of multidrug-resistant P-glycoprotein with an organotechnetium complex. Cancer Res 1993;53:977-84.
40. Moretti J, Azaloux H, Boisseron D, Kouyoumdjian J, Vilcoq J. Primary breast cancer imaging with technetium-99m sestamibi and its relation with P-glycoprotein overexpression. Eur J Nucl Med 1996;23:980-6.
41. Barbarics E, Kronauge J, Cohen D, Davison A, Jones A, Croop J. Characterization of P-glycoprotein transport and inhibition in vivo. Cancer Res 1998;58:276-82.
42. Del Vecchio S, Ciarmello A, Potena MI, Carriero MV, Mainolfi C, Botti G, et al. In vivo detection of multidrug-resistant (MDR1) phenotype by technetium-99m sestamibi scan in untreated breast cancer patients. Eur J Nucl Med 1997;24: 150-9.
43. Ciarmiello A, Vecchio SD, Silvestro P, Potenta M, Carriero M, Thomas R, et al. Tumor clearance of technetium 99m-sestamibi as a predictor of response to neoadjuvant chemotherapy for locally advanced breast cancer. J Clin Oncol 1998;16:1677-83.
44. Gralow JR, Zapf ML, Ellis GK, Livingston RB, Gown AM. Alterations in breast cancer protein expression following neoadjuvant doxorubicin-based chemotherapy. Breast Cancer Res Treat 1997;46:75.